secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001171843-23-006800
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences completes Phase 3 enrollment for simufilam; Q3 net loss $25.7M
-------------------------------------------------------------------------------

- Enrollment completed: 1,929 patients randomized across two Phase 3 trials of simufilam for Alzheimer's.
- Top-line results expected year-end 2024 (52-week trial) and mid-2025 (76-week trial).
- Cash and equivalents $142.4M at Sept 30, 2023; no debt.
- Q3 net loss $25.7M ($0.61/sh) vs $20.3M ($0.51/sh) in Q3 2022, driven by higher clinical costs.
- Interim MRI safety data suggests simufilam not associated with ARIA; DSMB recommends continuation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000117184323006800/0001171843-23-006800-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000117184323006800/f8k_110723.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-006800

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer